Literature DB >> 20505332

Dual-targeting of mTOR and HSP90 for cancer therapy: facing oncogenic feed-back-loops and acquired mTOR resistance.

Oliver Stoeltzing.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20505332     DOI: 10.4161/cc.9.11.11924

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  6 in total

1.  mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors.

Authors:  Yanjie Zhang; X F Steven Zheng
Journal:  Cell Cycle       Date:  2012-02-01       Impact factor: 4.534

Review 2.  PEG-b-PLA micelles and PLGA-b-PEG-b-PLGA sol-gels for drug delivery.

Authors:  Hyunah Cho; Jieming Gao; Glen S Kwon
Journal:  J Control Release       Date:  2015-12-15       Impact factor: 9.776

3.  Examination of Gossypol-Pluronic Micelles as Potential Radiosensitizers.

Authors:  Keishiro Tomoda; Carol Chiang; Kevin R Kozak; Glen S Kwon
Journal:  AAPS J       Date:  2015-08-06       Impact factor: 4.009

4.  Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging.

Authors:  Olga V Leontieva; Geraldine M Paszkiewicz; Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2012-12       Impact factor: 5.682

Review 5.  Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Richard A Franklin; Giuseppe Montalto; Melchiorre Cervello; Massimo Libra; Saverio Candido; Grazia Malaponte; Maria C Mazzarino; Paolo Fagone; Ferdinando Nicoletti; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Francesca Chiarini; Camilla Evangelisti; Lucio Cocco; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-10

6.  Insights from yeast into whether the inhibition of heat shock transcription factor (Hsf1) by rapamycin can prevent the Hsf1 activation that results from treatment with an Hsp90 inhibitor.

Authors:  Stefan H Millson; Peter W Piper
Journal:  Oncotarget       Date:  2014-07-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.